Thus, chemotherapies could have contributed at least in part to the observation of some of the predicted MUC4 mutations in our cohort, but since the vast majority of our initial tumors was not treated before surgery also chemotherapy-independent mutations of MUC4 could provide an advantage in astrocytoma development. The gene discussed is MUC4; the disease is astrocytoma (excluding glioblastoma).